| Oct 31 |
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2024 Earnings Call Transcript
|
| Oct 31 |
Madrigal stock jumps 13% after Rezdiffra Q3 sales beat estimates
|
| Oct 31 |
Madrigal Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Oct 31 |
Madrigal: Q3 Earnings Snapshot
|
| Oct 31 |
Madrigal Pharmaceuticals GAAP EPS of -$4.92 beats by $2.00, revenue of $62.2M beats by $27.79M
|
| Oct 31 |
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
|
| Oct 30 |
Madrigal Pharmaceuticals Q3 2024 Earnings Preview
|
| Oct 30 |
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
|
| Oct 28 |
Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings
|
| Oct 24 |
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
|
